A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel (Oral Paclitaxel) Compared to Taxol (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic HER2 Negative Breast Cancer
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Paclitaxel (Primary) ; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms OPTIMAL; OPTIMAL 3
- Sponsors Daehwa Pharmaceutical
- 25 Jul 2024 Planned End Date changed from 31 Mar 2024 to 31 Dec 2025.
- 26 Dec 2023 Planned End Date changed from 31 Mar 2022 to 31 Mar 2024.
- 26 Dec 2023 Planned primary completion date changed from 31 Dec 2020 to 30 Jan 2024.